Newron Pharmaceuticals - Evenamide catalyst approaching
Newron Pharmaceuticals is focused on the development of novel compounds for the treatment of various neurological conditions. Heading the R&D...
679 Views
Newron Pharmaceuticals - Evanamide potential expanding in schizophrenia
Newron Phamaceuticals has announced encouraging interim safety and efficacy data for the use of evanamide, a glutamate modulator, as an add-on...
681 Views
Newron Pharmaceuticals - Pivotal progress on schizophrenia therapy
Newron, a Switzerland-quoted Italian company, is developing evenamide (30mg twice per day) to meet the major unmet need for new therapies to help...
335 Views
Newron Pharmaceuticals - Evenamide validation underway
Newron is developing evenamide (30mg twice per day) as an add-on to treat poorly managed and refractory schizophrenia. A potentially pivotal Phase...
1.2k Views
Newron Pharmaceuticals - Evenamide Phase III at 30mg twice daily dose
Newron is developing evenamide as an add-on to existing anti-psychotic therapies to treat poorly managed and refractory schizophrenia. A...
995 Views